GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis  

作　　者：Yan Chen Ying-na Xu Chen-yu Ye Wen-bo Feng Qing-tong Zhou De-hua Yang Ming-wei Wang 

机构地区：[1]Department of Pharmacology,School of Basic Medical Sciences,Fudan University,Shanghai,200032,China [2]The CAS Key Laboratory of Receptor Research and The National Center for Drug Screening,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China [3]Research Center for Deepsea Bioresources,Sanya,572025,China [4]School of Life Science and Technology,ShanghaiTech University,Shanghai,201210,China

出　　处：《Acta Pharmacologica Sinica》2022年第5期1156-1166,共11页中国药理学报（英文版）

基　　金：This work was partially supported by National Natural Science Foundation of China 81872915(MWW),82073904(MWW),81773792(DHY),81973373(DHY),and 21704064(QTZ);National Science&Technology Major Project of China–Key New Drug Creation and Manufacturing Program 2018ZX09735–001(MWW)and 2018ZX09711002–002–005(DHY);the National Key Basic Research Program of China 2018YFA0507000(MWW);Science and Technology Commission of Shanghai Municipality 18431907100(MWW);Novo Nordisk-CAS Research Fund grant NNCAS-2017–1-CC(DHY)and SA-SIBS Scholarship Program(DHY).

摘　　要：Nonalcoholic steatohepatitis(NASH),as a severe form of nonalcoholic fatty liver disease(NAFLD),is characterized by liver steatosis,inflammation,hepatocellular injury and different degrees of fibrosis.The pathogenesis of NASH is complex and multifactorial,obesity and type 2 diabetes mellitus(T2DM)have been implicated as major risk factors.Glucagon-like peptide-1 receptor(GLP-1R)is one of the most successful drug targets of T2DM and obesity,and its peptidic ligands have been proposed as potential therapeutic agents for NASH.In this article we provide an overview of the pathophysiology and management of NASH,with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH,including dual and triple agonists at GLP-1R,glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

关 键 词：NAFLD NASH GLP-1R GLP-1 mimetics dual agonists triple agonists GPCR 

分 类 号：R575.5[医药卫生—消化系统]